… Erlotinib (OSI-774, Tarceva™, OSI Pharmaceuticals in collaboration with Genentech and
Roche) potently and reversibly inhibits EGFR tyrosine kinase activity of both wild-type EGFR …

… Gefitinib (ZD1839), is a small quinazoline-derivative, reversible inhibitor of EGFR TK
activity, does not induce EGFR intemalization or degradation and does not reduce …

… Erlotinib is a low-molecular weight, orally bioavailable, quinazoline derivative that
selectively and reversibly inhibits the tyrosine kinase activity of EGFR [ 44 ]. Phase 1 studies in …

… cancer patients do not have mutant EGFR and do not respond to the currently available
EGFR inhibitors encourages additional research to develop novel small molecule inhibitors that …

… current inhibitors. In this review, the importance of targeting EGFR signaling pathway in
cancer … EAI001 57 is a novel allosteric EGFR inhibitor with potent activity against mutant EGFR …

… In epithelial cell physiology, EGFR is responsible for performing essential activities. One of
the most common alterations and overexpression in many human malignancies, it has been …

… that have been approved for clinical uses in cancer therapy. These drugs are classified
based on their chemical structures, target kinases, and pharmacological uses. The synthetic …

… p38 inhibitor 1, we identified EGFR inhibition as an … activity against p38, lead us to pick this
compound as a first lead structure for further improvements in terms of the inhibition of EGFR …

… in numerous tumors as breast cancer, lung cancer (especially lung adenocarcinoma),
colorectal cancer and in ovarian cancer [6-9]. Therefore, targeting cancer cells by EGFR inhibitors …

… variety of human cancers. EGFR inhibition is one of the key targets for cancer chemotherapy.
… were evaluated for EGFR kinase inhibition as well as antiproliferative activity against A549 …